Clinical Trials
6 trialsNCT03310879 2026-04-29
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05999994 2026-03-27
CAMPFIRE
Eli Lilly and Company
Phase 2 Recruiting
NCT05933395 2026-01-20
GERTRUDE
Dartmouth-Hitchcock Medical Center
Phase 2 Recruiting
NCT04534283 2024-08-07
A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.
Indiana University
Phase 2 Terminated
NCT03997448 2024-02-20
Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149
Big Ten Cancer Research Consortium
Phase 2 Terminated
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting